Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 22

recruiting
3 987
countries
28
conditions
2 109

820 trials match your criteria

Myocarditis+2

Recruiting

Study on the Use of Methylprednisolone Sodium Succinate for Treating Patients with Acute Myocarditis and Mildly Reduced Heart Function

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Sodium Chloride

Glioblastoma

Recruiting

Study on Lomustine with or without Additional Brain Radiation for Patients with Recurrent Glioblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years

Anaemia+4

Recruiting

Study on Long-Term Safety of Luspatercept for Patients with Myelodysplastic Syndrome, Beta-Thalassemia, or Myelofibrosis Who Previously Participated in Luspatercept Trials

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Luspatercept

Pruritus

Recruiting

Study on the Effectiveness and Safety of Dupilumab for Adults with Chronic Itch of Unknown Cause

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab

Study on the Effectiveness and Safety of Carboplatin, Pemetrexed, and Lorlatinib for ALK Positive Non-Small Cell Lung Cancer with Extracranial Progression

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on the Effects of Belimumab in Adults with Systemic Sclerosis-Associated Interstitial Lung Disease

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab

Study on the Effectiveness of Volrustomig in Women with High-Risk Locally Advanced Cervical Cancer After Chemoradiation Therapy

Registered drug
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Infliximab

Study Comparing MK-2870 and Pembrolizumab Combination to Pembrolizumab Alone for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid

Study of Axitinib and Nivolumab for Patients with Metastatic Renal Cell Carcinoma Not Responding Completely to Initial Treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib

Study on the Effects of Risankizumab and Adalimumab in Children with Active Juvenile Psoriatic Arthritis

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Adalimumab

Study of LN-145 (Tumor Infiltrating Lymphocytes) in patients with metastatic non-small-cell lung cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Study on the Long-Term Safety of Finerenone with ACE Inhibitors or ARBs for Children and Young Adults with Chronic Kidney Disease and Proteinuria

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Finerenone
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.